Dermatosis Papulosa Nigra

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

DermBiont
DermBiontMA - Boston
1 program
1
SM-020 gel 1.0%Phase 21 trial
Active Trials
NCT06099080Active Not Recruiting10Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
DermBiontSM-020 gel 1.0%

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

NCT06099080DermBiontSM-020 gel 1.0%

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Start: Nov 2023Est. completion: Jul 202410 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space